#AXON #GNCA #PTCT #ZYNE #ZGNX the biotech movers week of September 25 -29, 2017.
Last week Biotech performers
- AXON -72.47% ~ failed Phase 3 MINDSET
- GNCA +72.40% ~ Ceased GEN 003 and shifted towards Immunocology.
- ZYNE +34.19% ~ ZYN002 gel meets primary endpoint in Phase 2 Fragile X syndrome trial.
- PTCT +8.05% ~ - FDA meeting for Translana seen as negative by majority of Analysts & Social media's biotech gurus. Stock price gone deep red -23% to positive territory.
- ZGNX +172.23% (*Meets endpoint ZX008 of Phase 3 trial for Dravet syndome*)